

## **ADULT Medication Monograph**

## **Paracetamol**

(including combination product with codeine)

This document should be read in conjunction with this **DISCLAIMER** 

<u>Formulary: Restricted</u> (combination products containing codeine)

**Formulary: Unrestricted** 

## **A HIGH RISK Medication**

(combination products containing codeine)

| Class          | Paracetamol: analgesic   |                                     |  |  |
|----------------|--|-------------------------------------|--|--|
|                | Paracetamol with codeine: opioid analgesic   |                                     |  |  |
| Presentation   | Paracetamol Products   |                                     |  |  |
| i icaciitation | Form   | Strength                            |  |  |
|                | Tablet   | 500mg                               |  |  |
|                | Effervescent tablet  | 500mg                               |  |  |
|                | Mini capsule   | 500mg                               |  |  |
|                | Slow release tablet  | 665mg                               |  |  |
|                | Oral suspension  | 50mg/mL                             |  |  |
|                | Suppository  | 500mg, 250mg, 125mg                 |  |  |
|                | Infusion Bottle  | 1gin 100mL                          |  |  |
|                | Combination Product  |                                     |  |  |
|                | Form   | Strength                            |  |  |
|                | Tablet   | Paracetamol 500mg with codeine 30mg |  |  |
| Storage        | Store at room temperature, below 25°C  |                                     |  |  |
|                | Schedule 4 Restricted Medication   |                                     |  |  |
|                | (combinatio  | on product with codeine)            |  |  |
| Dose           | Doses are based on paracetamol.  |                                     |  |  |
|                | Pain and Fever Oral/Rectal: 500 - 1000mg every 4 to 6 hours; maximum 4g daily Oral Controlled Release (665mg): |                                     |  |  |
|                |  |                                     |  |  |
|                |  |                                     |  |  |
|                |  |                                     |  |  |
|                | 2 tablets every 6 to 8 hours swallowed whole. Maximum 6 tablets (3990mg) daily                                 |                                     |  |  |

|                | IV Infusion:  |   |  |  |  |
|----------------|---|---|--|--|--|
|                | >50 kg: 1g every 4 to 6 hours; maximum 4g daily   |   |  |  |  |
|                | <50 kg: 15mg/kg every 4 to 6 hours; maximum 60mg/kg daily   |   |  |  |  |
|                | Renal/hepatic impairment: ensure doses are at least 6 hours apart   |   |  |  |  |
|                | Maximum dose:   |   |  |  |  |
|                | Usual maximum dose in adults is 4g daily; doses up to 6g daily may be used in palliative care and for 3 to 5 days by specialist pain services for acute pain.   |   |  |  |  |
|                | Maximum daily dose of codeine: 240mg  |   |  |  |  |
| Administration | <u>Oral</u>   |   |  |  |  |
|                | Swallow controlled rele   | Swallow controlled release tablets whole; do not crush or chew.   |  |  |  |
|                |   |   |  |  |  |
|                | IV Infusion   |   |  |  |  |
|                | Refer to the <u>Australian Injectable Drugs Handbook</u>  |   |  |  |  |
| Pregnancy      | Paracetamol and Par   | Paracetamol and Paracetamol with codeine products   |  |  |  |
|                | 1 <sup>st</sup> Trimester:  | Safe to use   |  |  |  |
|                | 2 <sup>nd</sup> Trimester:  | Safe to use   |  |  |  |
|                | 3 <sup>rd</sup> Trimester:  | Safe to use   |  |  |  |
|                |   |   |  |  |  |
| Breastfeeding  | Paracetamol   | Safe to use   |  |  |  |
|                | Paracetamol with codeine  | Consider alternative – life-threatening adverse events have been reported, including death of a breastfed infant of a mother exposed to codeine |  |  |  |
| Monitoring     | 1   | When used at high doses for prolonged periods, monitor liver aminotransferase levels and signs of hepatotoxicity.                               |  |  |  |
|                | Higher than recommended doses can cause serious liver damage. Check that no other forms of paracetamol are prescribed (e.g. oral or rectal) and that the safe maximum total dose of paracetamol is not exceeded for adults and children.  Take care not to confuse the dose for IV paracetamol in mg and mL. If a dose is calculated in mg and given in mL, the patient will receive a 10-fold overdose. Calculate and double check the dose required before each administration. |   |  |  |  |
|                |   |   |  |  |  |
|                | Combination product with codeine:   |   |  |  |  |
|                | •   | Pain score and frequency of breakthrough pain relief use  |  |  |  |

|                     | a Dawal mayamanta   |  |  |  |  |
|---------------------|---|--|--|--|--|
|                     | Bowel movements  On detions a manufacture rate.   |  |  |  |  |
|                     | Sedation sore and respiratory rate  |  |  |  |  |
|                     | Dependence and tolerance  |  |  |  |  |
| Clinical Guidelines | KEMH O&G Clinical Guidelines:   |  |  |  |  |
| and Policies        | Breastfeeding challenges: Engorgement/Full, Lumpy Breasts   |  |  |  |  |
|                     | Pregnancy Care: First Trimester Complications   |  |  |  |  |
|                     | Postoperative Anaesthetics  |  |  |  |  |
|                     | Labour and Postoperative Analgesia  |  |  |  |  |
|                     | Perineal Repair: Management of Third and Fourth Degree Perineal   |  |  |  |  |
|                     | Trauma Postnatal Care: Perineal Care  |  |  |  |  |
|                     |   |  |  |  |  |
|                     | Palliative Care   |  |  |  |  |
|                     |   |  |  |  |  |
|                     | KEMH Pharmaceutical & Medicines Management Guidelines:  |  |  |  |  |
|                     | Nurse/Midwife Initiated Medications   |  |  |  |  |
|                     | Endorsed Midwives Prescribing   |  |  |  |  |
| References          | Australian Medicines Handbook. Paracetamol. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Jul 10]. Available from: https://amhonline.amh.net.au/  |  |  |  |  |
|                     | Australian Medicines Handbook. Codeine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Jul 10]. Available from: https://amhonline.amh.net.au/  |  |  |  |  |
|                     | The Royal Women's Hospital. Paracetamol. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2020 Jul 10]. Available from: https://thewomenspbmg.org.au/  |  |  |  |  |
|                     | The Royal Women's Hospital. Codeine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2020 Jul 10]. Available from: https://thewomenspbmg.org.au/  |  |  |  |  |
|                     | Therapeutic Goods Administration. Safety review: Codeine use in children and ultra-rapid metabolisers [Internet]. Canberra, ACT: Therapeutic Goods Administration; 2017 [cited 2020 Jul 10]. Available from: https://www.tga.gov.au/alert/safety-review-codeine-use-children-and-ultra-rapid-metabolisers |  |  |  |  |

| Keywords:             | Paracetamol, Panadol, Panadeine, Digesic, Acetaminophen, Pain, Fever, analgesia, panadeine forte, codeine, paracetamol infusion, Acetaminophen infusion, IV paracetamol |                   |          |  |  |
|-----------------------|---|-------------------|----------|--|--|
| Publishing:           |   |                   |          |  |  |
| Document owner:       | Chief Pharmacist  |                   |          |  |  |
| Author / Reviewer:    | KEMH Pharmacy Department  |                   |          |  |  |
| Date first issued:    | July 2015   | Version:          | 3.0      |  |  |
| Last reviewed:        | Oct 2017, Jul 2020  | Next review date: | Jul 2023 |  |  |
| Endorsed by:          | Medicines and Therapeutics Committee  | Date:             | Jul 2020 |  |  |
| Standards Applicable: | NSQHS Standards: 1 Governance, 4 Medication Safety  |                   |          |  |  |

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email <a href="mailto:KEMH.PharmacyAdmin@health.wa.gov.au">KEMH.PharmacyAdmin@health.wa.gov.au</a>

© Department of Health Western Australia 2020